BR112017015788A2 - composição sólida, e, método de fabricação para uma composição sólida - Google Patents

composição sólida, e, método de fabricação para uma composição sólida

Info

Publication number
BR112017015788A2
BR112017015788A2 BR112017015788-8A BR112017015788A BR112017015788A2 BR 112017015788 A2 BR112017015788 A2 BR 112017015788A2 BR 112017015788 A BR112017015788 A BR 112017015788A BR 112017015788 A2 BR112017015788 A2 BR 112017015788A2
Authority
BR
Brazil
Prior art keywords
solid composition
manufacturing
phenyl
pyrrole
carboxamide
Prior art date
Application number
BR112017015788-8A
Other languages
English (en)
Japanese (ja)
Other versions
BR112017015788B1 (pt
Inventor
Tanabe Hideaki
Yamada Mina
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of BR112017015788A2 publication Critical patent/BR112017015788A2/pt
Publication of BR112017015788B1 publication Critical patent/BR112017015788B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção aborda o problema de prover uma composição sólida estabilizada de pirrole carboxamida. para resolver este problema, é provida uma composição sólida para uso medicinal que compreende (s)-1-(2-hidroxietil)-4-metil-n-[4-(metilsulfonil)fenil]-5-[2-(trifluorometil)fenil]-1h-pirrole-3-carboxamida opcionalmente em conjunto com aditivo(s).
BR112017015788-8A 2015-01-26 2016-01-25 Composição sólida, e, método de fabricação para uma composição sólida BR112017015788B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-012252 2015-01-26
JP2015012252 2015-01-26
PCT/JP2016/051956 WO2016121664A1 (ja) 2015-01-26 2016-01-25 ピロールカルボキサミドの固形組成物

Publications (2)

Publication Number Publication Date
BR112017015788A2 true BR112017015788A2 (pt) 2018-03-27
BR112017015788B1 BR112017015788B1 (pt) 2023-05-16

Family

ID=56543277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015788-8A BR112017015788B1 (pt) 2015-01-26 2016-01-25 Composição sólida, e, método de fabricação para uma composição sólida

Country Status (11)

Country Link
US (1) US10034855B2 (pt)
EP (1) EP3251669B1 (pt)
JP (1) JP6707471B2 (pt)
KR (1) KR102488167B1 (pt)
CN (1) CN107205984B (pt)
BR (1) BR112017015788B1 (pt)
CA (1) CA2973944C (pt)
ES (1) ES2832465T3 (pt)
HK (1) HK1247826A1 (pt)
TW (1) TWI686195B (pt)
WO (1) WO2016121664A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3506276C1 (de) * 1985-02-22 1986-04-24 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Direkttablettiermittel
FR2752162B1 (fr) * 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
MXPA06014587A (es) * 2004-06-17 2007-04-27 Forest Laboratories Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
PT1773768T (pt) * 2004-07-30 2018-11-30 Exelixis Inc Derivados de pirrol como agentes farmacêuticos
KR20140048337A (ko) 2007-04-09 2014-04-23 다이이찌 산쿄 가부시키가이샤 피롤 유도체의 아트로프 이성체
JP2010111657A (ja) * 2008-10-07 2010-05-20 Daiichi Sankyo Co Ltd ピロール誘導体のアトロプ異性体を含有する医薬
EP2359813A1 (en) * 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
JP5854371B2 (ja) * 2012-10-12 2016-02-09 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤
JP6027911B2 (ja) * 2013-02-18 2016-11-16 フロイント産業株式会社 賦形剤造粒物及びその製造方法、並びに錠剤
JP6107226B2 (ja) * 2013-02-26 2017-04-05 ニプロ株式会社 医薬組成物
JP5689192B2 (ja) * 2014-02-21 2015-03-25 大日本住友製薬株式会社 光安定性の向上した組成物

Also Published As

Publication number Publication date
EP3251669B1 (en) 2020-09-02
KR20170104486A (ko) 2017-09-15
CA2973944C (en) 2019-07-30
US10034855B2 (en) 2018-07-31
US20170319544A1 (en) 2017-11-09
TWI686195B (zh) 2020-03-01
TW201630601A (zh) 2016-09-01
ES2832465T3 (es) 2021-06-10
CA2973944A1 (en) 2016-08-04
EP3251669A1 (en) 2017-12-06
WO2016121664A1 (ja) 2016-08-04
EP3251669A4 (en) 2018-07-25
JPWO2016121664A1 (ja) 2017-11-02
BR112017015788B1 (pt) 2023-05-16
JP6707471B2 (ja) 2020-06-10
CN107205984A (zh) 2017-09-26
KR102488167B1 (ko) 2023-01-12
CN107205984B (zh) 2019-11-12
HK1247826A1 (zh) 2018-10-05

Similar Documents

Publication Publication Date Title
CY1121182T1 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
CL2016000925A1 (es) Inhibidores de bromodominio
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
AR101994A1 (es) COMPUESTOS DE PIRROLIDINA ANTAGONISTAS DE INTEGRINA avb6
CY1124427T1 (el) Συνθεση omecamtiv mecarbil
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2008002998A1 (es) Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
CL2012000937A1 (es) Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad.
HUE041725T2 (hu) (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
IN2013MU02905A (pt)
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
CO6650346A2 (es) Composiciones de tetraciclina
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
EA201990158A1 (ru) Производные бензодиоксана и их фармацевтическое применение
PL3643718T3 (pl) Związek heterocykliczny i jego zastosowanie jako dodatniego modulatora allosterycznego względem cholinergicznego receptora muskarynowego m1
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2015003515A1 (es) 4-(5-(4-clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol-3-il)bencenosulfonamida como modulador de nachr alfa 7.
BR112016026470A2 (pt) Composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
EA201890847A1 (ru) Композиции и способы ингибирования бета-лактамазы

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/01/2016, OBSERVADAS AS CONDICOES LEGAIS